We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
story of the week
Published in Brain Cancer

Journal Scan / Research · November 09, 2020

Dose-Dense Temozolomide + Lapatinib for Recurrent Low-Grade and Anaplastic Supratentorial, Infratentorial, and Spinal Cord Ependymoma

Neuro-oncology

 

Additional Info

Neuro-oncology
A Phase II Study of Dose-Dense Temozolomide and Lapatinib for Recurrent Low-Grade and Anaplastic Supratentorial, Infratentorial, and Spinal Cord Ependymoma
Neuro-oncology 2020 Oct 21;[EPub Ahead of Print], MR Gilbert, Y Yuan, J Wu, T Mendoza, E Vera, A Omuro, F Lieberman, HI Robins, ER Gerstner, J Wu, PY Wen, T Mikkelsen, K Aldape, TS Armstrong

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading